




RealRate

PHARMACEUTICAL 2012

Sonoma Pharmaceuticals Inc
Rank 145 of 196



The relative strengths and weaknesses of Sonoma Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Sonoma Pharmaceuticals Inc compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 9.6% points. The greatest weakness of Sonoma Pharmaceuticals Inc is the variable Stockholders Equity, reducing the Economic Capital Ratio by 121% points.

The company's Economic Capital Ratio, given in the ranking table, is 138%, being 96% points below the market average of 234%.

Input Variable	Value in 1000 USD
Assets, Current	7,809
Cost of Goods Sold	3,613
Intangible Assets	0
Liabilities, Current	4,415
Liabilities, Non-Current	1,638
Other Assets	53
Other Compr. Net Income	87
Other Expenses	581
Other Liabilities	910
Other Net Income	138
Other Revenues	9,754
Property and Equipment	802
Research and Development	2,046
Selling, General and Administrative Expense	11,600

Output Variable	Value in 1000 USD
Assets	8,664
Liabilities	6,963
Expenses	17,840
Revenues	9,754
Stockholders Equity	1,701
Net Income	-7,948
Comprehensive Net Income	-7,904
BaseVar	21,723
ECR before Limited Liability	-54%
Economic Capital Ratio	138%